喹诺酮类药物WCK 771对近期美国医院和社区获得性不同耐药类型金黄色葡萄球菌病原体的体外活性。
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
作者信息
Bhagwat Sachin S, McGhee Pamela, Kosowska-Shick Klaudia, Patel Mahesh V, Appelbaum Peter C
机构信息
Wockhardt Research Center, Aurangabad, India.
出版信息
Antimicrob Agents Chemother. 2009 Feb;53(2):811-3. doi: 10.1128/AAC.01150-08. Epub 2008 Nov 24.
Abstract
WCK 771 demonstrated MIC(50) and MIC(90)s of 0.03 and 1 microg/ml, respectively, against 297 recent U.S. community-acquired and hospital strains of Staphylococcus aureus, irrespective of quinolone or glycopeptide resistance. Against quinolone-resistant strains, MIC(90)s of WCK 771 and moxifloxacin were 1 and 16 microg/ml, respectively.
摘要
WCK 771对297株近期来自美国社区获得性和医院感染的金黄色葡萄球菌菌株，无论其对喹诺酮类或糖肽类是否耐药，其MIC(50)和MIC(90)分别为0.03和1微克/毫升。对于喹诺酮耐药菌株，WCK 771和莫西沙星的MIC(90)分别为1和16微克/毫升。
相似文献
1
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.喹诺酮类药物WCK 771对近期美国医院和社区获得性不同耐药类型金黄色葡萄球菌病原体的体外活性。
Antimicrob Agents Chemother. 2009 Feb;53(2):811-3. doi: 10.1128/AAC.01150-08. Epub 2008 Nov 24.
2
In vitro activity of the new quinolone WCK 771 against staphylococci.新型喹诺酮类药物WCK 771对葡萄球菌的体外活性
Antimicrob Agents Chemother. 2004 Sep;48(9):3338-42. doi: 10.1128/AAC.48.9.3338-3342.2004.
3
Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.三环氟喹诺酮类药物WCK 771在动物感染模型中的抗葡萄球菌活性。
Antimicrob Agents Chemother. 2004 Dec;48(12):4754-61. doi: 10.1128/AAC.48.12.4754-4761.2004.
4
The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.抗耐甲氧西林金黄色葡萄球菌喹诺酮类药物WCK 771对序贯选择的突变体具有强大活性，对耐喹诺酮金黄色葡萄球菌的突变选择窗较窄，且优先靶向DNA旋转酶。
Antimicrob Agents Chemother. 2006 Nov;50(11):3568-79. doi: 10.1128/AAC.00641-06. Epub 2006 Aug 28.
5
In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms.左氧氟沙星（WCK 771）对耐甲氧西林和喹诺酮类药物的金黄色葡萄球菌生物膜的体外杀菌活性。
J Med Microbiol. 2019 Aug;68(8):1129-1136. doi: 10.1099/jmm.0.000999. Epub 2019 Jun 26.
6
Levonadifloxacin (WCK 771) exerts potent intracellular activity against in THP-1 monocytes at clinically relevant concentrations.左氧氟沙星（WCK 771）在临床相关浓度下对 THP-1 单核细胞内的 发挥强大的活性。
J Med Microbiol. 2019 Dec;68(12):1716-1722. doi: 10.1099/jmm.0.001102. Epub 2019 Nov 5.
7
Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619.医疗保健相关和社区相关的耐甲氧西林葡萄球菌对新型去F(6)-喹诺酮DX-619的敏感性。
J Antimicrob Chemother. 2007 Dec;60(6):1384-7. doi: 10.1093/jac/dkm361. Epub 2007 Sep 21.
8
Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.使用体外模型比较头孢比普与万古霉素对耐甲氧西林金黄色葡萄球菌（MRSA）、万古霉素中介金黄色葡萄球菌（VISA）和耐万古霉素金黄色葡萄球菌（VRSA）的药效学活性。
J Antimicrob Chemother. 2009 Aug;64(2):364-9. doi: 10.1093/jac/dkp176. Epub 2009 May 19.
9
Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus.社区获得性金黄色葡萄球菌的毒力特征以及莫西沙星单独及联合应用对社区获得性和医院获得性耐甲氧西林和甲氧西林敏感金黄色葡萄球菌的体外活性。
J Med Microbiol. 2008 Apr;57(Pt 4):452-456. doi: 10.1099/jmm.0.47580-0.
10
Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.氟喹诺酮类药物对金黄色葡萄球菌高水平耐苯唑西林的二项选择。
Int J Antimicrob Agents. 2010 Sep;36(3):216-21. doi: 10.1016/j.ijantimicag.2010.04.014. Epub 2010 Jul 14.
引用本文的文献
1
Staph wars: the antibiotic pipeline strikes back.葡萄球菌之战：抗生素管道奋起反击。
Microbiology (Reading). 2023 Sep;169(9). doi: 10.1099/mic.0.001387.
2
Potential new fluoroquinolone treatments for suspected bacterial keratitis.疑似细菌性角膜炎的潜在新型氟喹诺酮类治疗方法。
BMJ Open Ophthalmol. 2022 Jul;7(1). doi: 10.1136/bmjophth-2022-001002.
3
Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections and Bloodstream Infections Caused by : A Comprehensive Review of the Evidence.新兴的针对由[病原体]引起的急性细菌性皮肤及皮肤结构感染和血流感染的治疗选择：证据的全面综述
Infect Drug Resist. 2022 Apr 22;15:2137-2157. doi: 10.2147/IDR.S318322. eCollection 2022.
4
Uptake of Ozenoxacin and Other Quinolones in Gram-Positive Bacteria.阳性菌中奥昔康唑和其他喹诺酮类药物的摄取。
Int J Mol Sci. 2021 Dec 12;22(24):13363. doi: 10.3390/ijms222413363.
5
Antibiotics in the clinical pipeline in October 2019.2019 年 10 月处于临床研发管线中的抗生素。
J Antibiot (Tokyo). 2020 Jun;73(6):329-364. doi: 10.1038/s41429-020-0291-8. Epub 2020 Mar 10.
6
Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model.左氧氟沙星，一种新型苯并喹啉氟喹诺酮，在人全血检测和小鼠急性肺损伤模型中调节脂多糖诱导的炎症反应。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.00084-20.
7
Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.耐多药革兰氏阳性微生物感染的新兴治疗选择
Microorganisms. 2020 Jan 30;8(2):191. doi: 10.3390/microorganisms8020191.
8
Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.左旋纳氟沙星，一种新型广谱抗耐甲氧西林金黄色葡萄球菌苯并喹嗪类喹诺酮药物：当前证据综述
Drug Des Devel Ther. 2019 Dec 24;13:4351-4365. doi: 10.2147/DDDT.S229882. eCollection 2019.
9
Overview of methicillin resistant mediated bone and joint infections in India.印度耐甲氧西林介导的骨与关节感染概述。
Orthop Rev (Pavia). 2019 Jun 20;11(2):8070. doi: 10.4081/or.2019.8070. eCollection 2019 May 23.
10
Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model.左氧氟沙星对中性粒细胞减少症小鼠肺部感染金黄色葡萄球菌的药代动力学/药效学靶标。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00909-19. Print 2019 Aug.
本文引用的文献
1
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).1986年至2007年期间，密歇根州底特律市大都市区耐万古霉素金黄色葡萄球菌的特征分析。
J Clin Microbiol. 2008 Sep;46(9):2950-4. doi: 10.1128/JCM.00582-08. Epub 2008 Jul 16.
2
Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).耐甲氧西林金黄色葡萄球菌（MRSA）中糖肽类药物敏感性降低。
Int J Antimicrob Agents. 2007 Nov;30(5):398-408. doi: 10.1016/j.ijantimicag.2007.07.011. Epub 2007 Sep 20.
3
Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.一名患有心内膜炎患者体内一株对达托霉素不敏感的万古霉素中介金黄色葡萄球菌菌株的特征分析。
Antimicrob Agents Chemother. 2007 Sep;51(9):3445-8. doi: 10.1128/AAC.00559-07. Epub 2007 Jul 9.
4
The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.抗耐甲氧西林金黄色葡萄球菌喹诺酮类药物WCK 771对序贯选择的突变体具有强大活性，对耐喹诺酮金黄色葡萄球菌的突变选择窗较窄，且优先靶向DNA旋转酶。
Antimicrob Agents Chemother. 2006 Nov;50(11):3568-79. doi: 10.1128/AAC.00641-06. Epub 2006 Aug 28.
5
Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States.基于实验室的金黄色葡萄球菌当前耐药模式及趋势监测：2005年美国现状
Ann Clin Microbiol Antimicrob. 2006 Feb 9;5:2. doi: 10.1186/1476-0711-5-2.
6
Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus.不稳定的万古霉素异质性耐药在耐甲氧西林金黄色葡萄球菌临床分离株中很常见。
J Clin Microbiol. 2005 May;43(5):2494-6. doi: 10.1128/JCM.43.5.2494-2496.2005.
7
Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.三环氟喹诺酮类药物WCK 771在动物感染模型中的抗葡萄球菌活性。
Antimicrob Agents Chemother. 2004 Dec;48(12):4754-61. doi: 10.1128/AAC.48.12.4754-4761.2004.
8
In vitro activity of the new quinolone WCK 771 against staphylococci.新型喹诺酮类药物WCK 771对葡萄球菌的体外活性
Antimicrob Agents Chemother. 2004 Sep;48(9):3338-42. doi: 10.1128/AAC.48.9.3338-3342.2004.
9
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.对万古霉素敏感性降低的耐甲氧西林金黄色葡萄球菌引起的严重感染的治疗结果。
Clin Infect Dis. 2004 Feb 15;38(4):521-8. doi: 10.1086/381202. Epub 2004 Jan 29.
10
In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.新型氟喹诺酮类药物DK-507k的体外和体内抗菌活性
Antimicrob Agents Chemother. 2003 Dec;47(12):3750-9. doi: 10.1128/AAC.47.12.3750-3759.2003.
Zotero 插件